AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Avicanna Inc.

$0.08 -$0.08 (-48.64%)
OTC · 14 Sep 2026 14:25 UTC
Previous Close
$0.09
Day Range
$0.08$0.09
Year Range
$0.07$0.22
Market Cap
10.47M
AVG Volume
95.27K
Trailing/Forward PE
-3.4/-
PEG ratio
0.05
Dividend Yield
-
Next Earnings Date
2026-11-13
Primary Exchange
Other OTCUS
Revenue (CAD) · TTM
010M20M30M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF Revenue (CAD) · TTM by quarter
PeriodRevenue (CAD) · TTM
26 Q225.33M
26 Q125.85M
25 Q425.47M
25 Q325.5M
25 Q225.37M
25 Q125.34M
24 Q425.46M
24 Q324.9M
24 Q224.87M
24 Q122.07M
Net Income (CAD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF Net Income (CAD) · TTM by quarter
PeriodNet Income (CAD) · TTM
26 Q2-3.91M
26 Q1-3.59M
25 Q4-2.93M
25 Q3-1.88M
25 Q2-1.28M
25 Q1-2.53M
24 Q4-3.39M
24 Q3-6.1M
24 Q2-6.73M
24 Q1-6.55M
Operating Income (CAD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF Operating Income (CAD) · TTM by quarter
PeriodOperating Income (CAD) · TTM
26 Q2-3.74M
26 Q1-3.35M
25 Q4-2.76M
25 Q3-3.2M
25 Q2-2.6M
25 Q1-3.53M
24 Q4-4.23M
24 Q3-5.21M
24 Q2-5.72M
24 Q1-5.75M
EBITDA (CAD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF EBITDA (CAD) · TTM by quarter
PeriodEBITDA (CAD) · TTM
26 Q2-3.04M
26 Q1-2.63M
25 Q4-2.01M
25 Q3-1.05M
25 Q2-378.6K
25 Q1-1.47M
24 Q4-2.42M
24 Q3-5.44M
24 Q2-5.98M
24 Q1-5.88M
Cash Flows (CAD) · TTM
-4M-3M-2M-1M01M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF Cash Flows (CAD) · TTM by quarter
PeriodCash Flows (CAD) · TTM
26 Q2-3.36M
26 Q1-2.25M
25 Q4-1.44M
25 Q3-1.79M
25 Q2-1.19M
25 Q1-3.18M
24 Q4-2.95M
24 Q3-3.3M
24 Q2-597.58K
24 Q1180.65K
EPS (CAD) · TTM
-0.08-0.06-0.04-0.02024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF EPS (CAD) · TTM by quarter
PeriodEPS (CAD) · TTM
26 Q2-0.03
26 Q1-0.03
25 Q4-0.02
25 Q3-0.02
25 Q2-0.01
25 Q1-0.03
24 Q4-0.04
24 Q3-0.07
24 Q2-0.07
24 Q1-0.07
Expenses (CAD) · TTM
05M10M15M20MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF Expenses (CAD) · TTM by quarter
PeriodExpenses (CAD) · TTM
26 Q216.71M
26 Q116.18M
25 Q415.63M
25 Q316.09M
25 Q215.84M
25 Q116.43M
24 Q416.65M
24 Q316.07M
24 Q216.14M
24 Q115.27M
Shares Outstanding (CAD) · TTM
-2M-1.5M-1M-500K0500KBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
AVCNF Shares Outstanding (CAD) · TTM by quarter
PeriodShares Outstanding (CAD) · TTM
26 Q2-857.72K
26 Q1-1.03M
25 Q4-1.17M
25 Q3-1.03M
25 Q2-821.54K
25 Q1-1.44M
24 Q4-1.57M
24 Q3-1.3M
24 Q2-1.37M
24 Q1-1.08M
Free Cash Flow Yield
-20%-15%-10%-5%0%med -9.84%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AVCNF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-15.85%
Sep 26-14.46%
Aug 26-15.12%
Aug 26-14.1%
Aug 26-14.21%
Aug 26-14.65%
Jul 26-14.55%
Jul 26-13.47%
Jul 26-14.07%
Jul 26-13.92%
Jul 26-14.99%
Jun 26-10.04%
Jun 26-9.3%
Jun 26-10.09%
Jun 26-10.48%
May 26-9.66%
May 26-8.94%
May 26-9.14%
May 26-8.95%
May 26-8.11%
Apr 26-8.28%
Apr 26-8.04%
Apr 26-7.5%
Apr 26-8.28%
Mar 26-10.02%
Mar 26-9.13%
Mar 26-8.67%
Mar 26-8.41%
Feb 26-8.27%
Feb 26-9.19%
Feb 26-8.59%
Feb 26-8.44%
Jan 26-7.65%
Jan 26-6.89%
Jan 26-7.18%
Jan 26-6.6%
Jan 26-7.01%
Dec 25-4.7%
Dec 25-4.58%
Dec 25-4.72%
Dec 25-4.71%
Nov 25-4.6%
Nov 25-4.48%
Nov 25-4.35%
Nov 25-4.23%
Oct 25-3.99%
Oct 25-3.99%
Oct 25-3.98%
Oct 25-3.98%
Oct 25-4.14%
Sep 25-11.46%
Sep 25-11.25%
Sep 25-10.46%
Sep 25-10.51%
Aug 25-10.47%
Aug 25-10.3%
Aug 25-10.81%
Aug 25-10.53%
Aug 25-10.4%
Jul 25-9.57%
Jul 25-11.07%
Jul 25-11.81%
Jul 25-10.67%
Jun 25-10.88%
Jun 25-11.3%
Jun 25-12.3%
Jun 25-12.9%
May 25-10.9%
May 25-10.03%
May 25-10.27%
May 25-11.76%
May 25-12.14%
Apr 25-12.44%
Apr 25-12.26%
Apr 25-13.37%
Apr 25-12.88%
Mar 25-10.74%
Mar 25-9.41%
Mar 25-9.3%
Mar 25-9.12%
Feb 25-10.59%
Feb 25-11.92%
Feb 25-13.12%
Feb 25-11.99%
Jan 25-12.52%
Jan 25-10.61%
Jan 25-10.87%
Jan 25-13.68%
Jan 25-10.4%
Dec 24-2.18%
Dec 24-1.97%
Dec 24-1.65%
Dec 24-2.24%
Nov 24-1.82%
Nov 24-2.45%
Nov 24-2.69%
Nov 24-2.29%
Nov 24-2.09%
Oct 24-2.22%
Oct 24-2.17%
Price to Sales
0.50.7511.251.5med 1.01Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AVCNF Price to Sales by quarter
PeriodPrice to Sales
Sep 260.55
Sep 260.6
Aug 260.58
Aug 260.62
Aug 260.61
Aug 260.59
Jul 260.6
Jul 260.65
Jul 260.62
Jul 260.63
Jul 260.58
Jun 260.56
Jun 260.61
Jun 260.56
Jun 260.54
May 260.58
May 260.63
May 260.62
May 260.63
May 260.7
Apr 260.68
Apr 260.7
Apr 260.75
Apr 260.68
Mar 260.7
Mar 260.77
Mar 260.81
Mar 260.83
Feb 260.85
Feb 260.76
Feb 260.82
Feb 260.83
Jan 260.92
Jan 261.02
Jan 260.98
Jan 261.06
Jan 261
Dec 251
Dec 251.02
Dec 250.99
Dec 251
Nov 251.02
Nov 251.05
Nov 251.08
Nov 251.11
Oct 251.18
Oct 251.17
Oct 251.18
Oct 251.18
Oct 251.13
Sep 251.1
Sep 251.12
Sep 251.2
Sep 251.19
Aug 251.2
Aug 251.22
Aug 251.16
Aug 251.19
Aug 251.21
Jul 251.31
Jul 251.13
Jul 251.06
Jul 251.18
Jun 251.07
Jun 251.03
Jun 250.94
Jun 250.9
May 251.06
May 251.15
May 251.13
May 250.99
May 250.95
Apr 250.93
Apr 250.95
Apr 250.87
Apr 250.9
Mar 251.23
Mar 251.41
Mar 251.43
Mar 251.45
Feb 251.25
Feb 251.11
Feb 251.01
Feb 251.11
Jan 251.06
Jan 251.25
Jan 251.22
Jan 250.97
Jan 251.28
Dec 241.1
Dec 241.22
Dec 241.45
Dec 241.07
Nov 241.32
Nov 240.98
Nov 240.89
Nov 241.05
Nov 241.15
Oct 241.08
Oct 241.11
Price/Operating Cashflow
30405060med 40.33Jul 24Jul 24Aug 24Aug 24Aug 24Sep 24Sep 24
AVCNF Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2438.25
Sep 2448.8
Sep 2442.76
Sep 2445.3
Aug 2446.92
Aug 2438.54
Aug 2439.91
Aug 2434.16
Aug 2434.85
Jul 2437.2
Jul 2444.04
Jul 2457.04
Jul 2440.33
Price to Book
12345med 2.49Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AVCNF Price to Book by quarter
PeriodPrice to Book
Sep 261.11
Sep 261.21
Aug 261.16
Aug 261.24
Aug 261.24
Aug 261.2
Jul 261.21
Jul 261.3
Jul 261.25
Jul 261.26
Jul 261.17
Jun 261.26
Jun 261.36
Jun 261.25
Jun 261.2
May 261.31
May 261.41
May 261.38
May 261.41
May 261.56
Apr 261.52
Apr 261.57
Apr 261.68
Apr 261.53
Mar 261.52
Mar 261.67
Mar 261.76
Mar 261.82
Feb 261.85
Feb 261.66
Feb 261.78
Feb 261.81
Jan 261.99
Jan 262.21
Jan 262.13
Jan 262.31
Jan 262.18
Dec 252.33
Dec 252.39
Dec 252.32
Dec 252.33
Nov 252.38
Nov 252.45
Nov 252.52
Nov 252.59
Oct 252.75
Oct 252.75
Oct 252.76
Oct 252.75
Oct 252.65
Sep 252.57
Sep 252.61
Sep 252.81
Sep 252.8
Aug 252.81
Aug 252.85
Aug 252.72
Aug 252.79
Aug 252.83
Jul 253.07
Jul 252.65
Jul 252.49
Jul 252.76
Jun 252.78
Jun 252.68
Jun 252.46
Jun 252.35
May 252.78
May 253.02
May 252.95
May 252.57
May 252.49
Apr 252.43
Apr 252.47
Apr 252.26
Apr 252.35
Mar 253.34
Mar 253.82
Mar 253.86
Mar 253.94
Feb 253.39
Feb 253.01
Feb 252.74
Feb 252.99
Jan 252.87
Jan 253.39
Jan 253.3
Jan 252.63
Jan 253.45
Dec 243.44
Dec 243.81
Dec 244.54
Dec 243.35
Nov 244.12
Nov 243.06
Nov 242.79
Nov 243.27
Nov 243.6
Oct 243.39
Oct 243.46
Avicanna Inc.
AVCNF
Stockpicker

Video analysis: AVCNF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: AVCNF

Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada

globenewswire.com · 9 Sep 2026

Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada

Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada

Avicanna Announces Closing of Strategic Non-Brokered Private Placement

globenewswire.com · 19 Aug 2026

Avicanna Announces Closing of Strategic Non-Brokered Private Placement

Strategic investment by pharmaceutical executive and life sciences investor Michael Porter Strategic investment by pharmaceutical executive and life sciences investor Michael Porter

Avicanna Reports Q2 2026 Financial Results

globenewswire.com · 14 Aug 2026

Avicanna Reports Q2 2026 Financial Results

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

globenewswire.com · 16 Jul 2026

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

globenewswire.com · 30 Jun 2026

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

globenewswire.com · 15 Jun 2026

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.